about
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialMelanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.Exosomes in cancer immunotherapy: preclinical data.Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemiaTreatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.The potential of exosomes in immunotherapy of cancer.CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.Dendritic cell derived-exosomes: biology and clinical implementations.Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effectsEcto-calreticulin in immunogenic chemotherapy.Dendritic cells and innate defense against tumor cells.Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.A novel dendritic cell subset involved in tumor immunosurveillance.Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.CD48 may serve as an accessory molecule for the activation of a subset of human gamma/delta T cells.Predictors of responses to immune checkpoint blockade in advanced melanomaImmune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.Malignant effusions and immunogenic tumour-derived exosomes.Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.BCR/ABL promotes dendritic cell-mediated natural killer cell activation.IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules.Potent immunomodulatory effects of the trifunctional antibody catumaxomab.An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.
P50
Q24801506-7567974E-9A0D-4AED-BF4D-0CA372CDBA63Q28553228-B1217618-06DF-4965-BBBD-6B22EB1356ADQ30358552-D25F3494-968F-4A2D-A07A-296BF5651833Q30668747-155A3C83-39AE-4E30-832F-B80027FFCDF1Q33421740-C8AC9AF9-99B3-4239-90E1-B4CF8E23632AQ34541173-2EBF3229-5BF8-4278-818F-E30D17E91A3AQ34542239-E820124A-D25E-48D5-B7D4-BF4E4DEC1D39Q34545292-DC2D8EE1-E6C0-48E4-8E74-1880FEEA37ACQ35109585-0E29A97B-34D3-4539-9844-5200C091FC32Q35833921-4B791859-C099-478E-9976-2C3FE5DB635EQ36199323-32490E4B-9276-4E4C-AE85-EB3DE6ACF2A4Q36403637-759148F7-4488-4DE4-8C6E-51497D9AD90EQ36523645-E46746FA-1EA7-4CFC-8DE4-4842AF817C36Q36694926-A3ACBBB4-0F45-4FCC-A417-ECB94AA51F42Q36694931-E639D9C9-8897-4D99-94A1-2EDC114147C3Q36949870-8AA6EDE3-91DB-492D-82A9-4D286D82BF0DQ36985600-C40CC78F-D941-4A99-B2DE-727B91663B2DQ36990570-6FB944EB-BD1E-4336-A822-679968E2CF77Q37044174-3FC8E47F-16B5-4258-9BAB-714D10129F0BQ39546314-EFD399D5-C5A7-462F-85AD-DEF69CDA51D7Q40323661-1EFD989F-9F1F-421A-ABC3-D466AE0548BCQ40592158-C65C96E4-6CD3-4755-8874-E7727B985A6FQ40737994-8EBE174A-E810-47EE-BB52-7ED4FD43E165Q41208860-B716EE2B-BF52-4247-87F6-69F69495CEC4Q41701241-F1E1355E-9E54-4635-915E-7D90A9F9FC5FQ43733739-708C7A3E-9876-44CC-A0A9-7B8570420396Q44082514-90893DD1-0FDB-401E-A3BD-112F79B86729Q44601660-39CDBFCC-AD4C-4D58-9BDC-677EB1444A25Q46058156-0264EB7A-3D21-4D3E-A930-672302440C2CQ46604695-F7910543-2A32-4EEF-8034-580C99BF95B6Q47644573-D8C44714-4E77-4607-9D6B-65385AC4E2C2Q50936255-02D983AC-6F7E-477E-B006-57AFDBF1368EQ51735061-327C81F2-3135-4DEE-BBE9-7AC71E434B72
P50
description
onderzoeker
@nl
name
Caroline Flament
@ast
Caroline Flament
@en
Caroline Flament
@es
Caroline Flament
@sl
type
label
Caroline Flament
@ast
Caroline Flament
@en
Caroline Flament
@es
Caroline Flament
@sl
prefLabel
Caroline Flament
@ast
Caroline Flament
@en
Caroline Flament
@es
Caroline Flament
@sl